Guava Technologies announced unexpectedly last week that Rajen Dalal, the company’s president and CEO for the last three years, has resigned.

Taking over for Dalal on an interim basis is John Walker, the chairman of Guava’s board of directors.

Last week, Dalal told Inside Bioassays that his decision to resign was primarily due to a disagreement about which markets Guava should commit the bulk of its money to over the coming year: drug-discovery tools or clinical diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.